Revolutionizing the Treatment of Aortic Arch Aneurysms
Bringing RIBS™ to the World
Bringing New Hope to Patients with Life-Threatening Diseases
Aortic arch aneurysms have long been considered among the most challenging conditions to treat with endovascular therapy.
To address this challenge, we are developing the RIBS™ Stent Graft System, an innovative endovascular system designed for the treatment of complex aortic arch aneurysms.
The system utilizes a unique approach combining retrograde in situ fenestration and branch stent-graft placement through cervical access, with the goal of preserving blood flow to the supra-aortic branches.
By expanding the possibilities of minimally invasive treatment, the RIBS™ Stent Graft System is intended to provide new treatment options for patients who have historically had limited endovascular alternatives.
RIBS™ Stent Graft System: Concept Movie
RIBS™ Is Redefining the Limits of Treatment.
Many patients with aortic aneurysms continue to face life-threatening risks because their treatment options remain limited. Among them, aortic arch aneurysms have been particularly challenging, as their complex anatomy has significantly restricted the use of minimally invasive endovascular treatment.
At RIBS, we are committed to fundamentally changing this reality through the development of the RIBS™ Stent Graft System. Designed to enable endovascular treatment in the aortic arch—an area that has long been difficult to treat with conventional technologies—our system has the potential to expand treatment options for patients with complex aortic disease.
Through this innovative approach, we aim to establish the next standard in aortic care.
Safer, less invasive treatment.
Reduced procedural risk and faster patient recovery.
Better quality of life for every patient.
Through the development of the RIBS Stent Graft System, we are committed to bringing new hope to patients who previously had limited treatment options and to advancing the future of cardiovascular care.
